New SARS-CoV-2 Variant PJ.2.1 Neutralized by XFG-Adapted Vaccine Boosters

The XFG-adapted Comirnaty booster effectively neutralizes the new SARS-CoV-2 saltation variant PJ.2.1, according to laboratory findings from German Primate Center researchers published this month in The Lancet Infectious Diseases.

The variant, spreading since May 2026, binds more strongly to human cells but remains vulnerable to vaccine-induced antibodies.

That combination — a virus that enters cells more efficiently yet is still blocked by the current vaccine — is the core finding. It answers a question that had been open since PJ.2.1 was first detected in Canada: whether antibodies from vaccinated people could stop it. Until now, it was unclear how efficiently the variant penetrates cells and how susceptible it is to neutralizing antibodies.

Booster blocks new variant effectively

  • The booster currently in use in Germany, adapted to the XFG variant, produced antibodies that effectively blocked PJ.2.1 in laboratory testing.
  • PJ.2.1 carries an unusually large number of spike protein mutations but shows no evidence, so far, of causing more severe disease or new symptoms.
  • Last season’s vaccine and the current one did not adequately inhibit a separate variant, BA.3.2, found mainly in children.

A variant born inside a long-term infection

SARS-CoV-2 usually evolves in small steps, with new variants differing from predecessors by only a few mutations in the spike protein — the structure the virus uses to attach to the ACE2 receptor, its entry point into human cells. PJ.2.1 is different. It is what researchers call a saltation variant: one carrying an unusually large number of mutations that lets it evade the antibody response particularly efficiently.

Such variants develop during long-term infections, where the virus has months to replicate inside a single person and gradually accumulate changes. PJ.2.1 traces back to an older viral lineage that has largely disappeared from circulation; the virus likely persisted in one chronically infected individual and underwent significant changes there.

The variant has been spreading since May 2026, first detected in Canada and then in the United States. A team led by infection biologists Markus Hoffmann and Stefan Pöhlmann of the German Primate Center — Leibniz Institute for Primate Research, working with Georg Behrens’s group at Hannover Medical School, tested how well it enters cells and how vaccine antibodies respond.

Prof. Dr. Stefan Pöhlmann and Dr. Markus Hoffmann, infection biologists at the German Primate Center
Photo: nachrichten.idw-online.de

Stronger cell entry, same antibody target

The laboratory results showed that PJ.2.1’s spike protein binds more strongly to the ACE2 receptor than the other variants studied. Consistent with that, it entered cells producing only small amounts of ACE2 more effectively than its competitors — a property the researchers interpret as a likely driver of its worldwide spread.

Despite that advantage, antibodies from people vaccinated with the XFG-adapted mRNA vaccine Comirnaty effectively inhibited the variant. The findings were published in the Journal of Infection and The Lancet Infectious Diseases; the Lancet paper, “Humoral immunity after mRNA SARS-CoV-2 XFG vaccination,” led by Christine Happle, appeared this month.

“Our results suggest that PJ.2.1 is likely spreading worldwide due to improved ACE2 binding. We assume that the XFG-adapted vaccine provides effective protection against PJ.2.1 as well as against the XFG viruses that are also circulating — at least as long as these viruses do not acquire mutations that allow them to evade the antibody response more effectively,” said Markus Hoffmann, German Primate Center — Leibniz Institute for Primate Research.

The researchers’ caution matters. Antibody neutralization measured in the laboratory is a proxy for protection; it does not by itself establish how well vaccination prevents symptomatic illness against this variant in the population. And the protection holds only as long as the virus does not pick up further immune-evading mutations.

Germany tested vaccine protectio
Photo: ua.news

The variant gaining ground across Europe

According to the German Primate Center’s release, PJ.2.1 is spreading rapidly in Canada, the United States and Spain, with rising prevalence in the Netherlands and France. Spread in Germany is expected. With infection rates there already high — Germany’s own COVID-19 traffic-light indicator stands at red — the variant has been detected in all age groups.

There is currently no evidence of more severe disease progression or new symptoms compared with other SARS-CoV-2 variants, the researchers said. That distinguishes the public health picture from 2020–2021, when variant emergence often coincided with changes in disease severity; here the concern is transmissibility, not virulence, based on what the sources report.

The gap the vaccine does not cover: BA.3.2

The study’s second finding is a warning. Neither the vaccine used last season nor the currently available one elicits an antibody response that efficiently blocks BA.3.2 from entering cells. That variant is detected primarily in children.

Stefan Pöhlmann from the German Primate Center said that since BA.3.2 is detected primarily in children, it should be investigated whether an additional component tailored to this variant could be included in future COVID-19 vaccines.

For regulators, that points toward the annual strain-selection process. In Germany, researchers found that antibodies produced after vaccination with the XFG-adapted mRNA vaccine Comirnaty effectively neutralize the new SARS-CoV-2 variant PJ.2.1, indicating that vaccination provides protection against the variant. Whether a BA.3.2 component joins future formulations is a question the researchers say should now be investigated; no regulatory decision on this has been announced in the source material.

Consult doctors on COVID vaccination timing

Anyone with symptoms of COVID-19 — or at higher risk of severe disease — should consult a healthcare professional about vaccination timing and treatment options. The researchers’ own caveat is the key limit: protection against PJ.2.1 could change if the variant acquires additional immune-evading mutations.

Researchers plan vaccine evaluation for BA.3.2

The variant’s spread in Germany is, in the researchers’ words, to be expected, and surveillance will show whether PJ.2.1 or BA.3.2 gains further ground this winter. The next concrete step the researchers themselves name is the evaluation of a BA.3.2-tailored component for future vaccines — a question now formally on the table.

References

  • Happle, C., Hoffmann, M., Stankov, M.V., et al. (2026). “Humoral immunity after mRNA SARS-CoV-2 XFG vaccination.” The Lancet Infectious Diseases. DOI: 10.1016/s1473-3099(26)00569-4. Read the study
  • German Primate Center — Leibniz Institute for Primate Research press release: “New SARS-CoV-2 Variant PJ.2.1: Vaccine Antibodies Provide Protection.”
  • News-Medical: Current booster vaccine protects against new PJ.2.1 SARS-CoV-2 variant.
  • Medical Xpress: “New SARS-CoV-2 variant PJ.2.1: Vaccine antibodies provide protection.”
Photo of author

Health Desk

Health Desk at Archyde.

Netflix’s “The Signal”: Astronaut Vanishes Leaving a Clue

Parag Agrawal Bets on Search Technology for AI Agents